Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Macro

Trump’s Drug-Pricing Plan Could Raise Global Costs and Limit Access to Medicines

by Team Lumida
May 16, 2025
in Macro
Reading Time: 4 mins read
A A
0
Tech Titans Pivot: Silicon Valley’s New Alliance in Trump’s Second Term

"Donald Trump" by Gage Skidmore is licensed under CC BY-SA 2.0

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  • President Trump’s drug-pricing plan aims to align U.S. drug costs with lower prices abroad, but experts warn it could lead to higher prices in Europe and reduced access in lower-income countries.
  • Wealthy European nations like Germany and Norway are expected to feel the impact first, with ripple effects on smaller markets in Central and Eastern Europe.
  • Drugmakers may delay or avoid launching new medicines in lower-cost markets to maintain higher U.S. prices, potentially harming global access to innovative treatments.
  • The plan relies on voluntary action and lacks specifics for implementation, raising questions about its feasibility and long-term impact.

What Happened?

President Trump signed an executive order on May 12 to reduce U.S. drug prices by benchmarking them to lower prices paid in other countries, a practice known as reference pricing. While the plan aims to ease the financial burden on Americans, it could have unintended global consequences.

Pharmaceutical companies may respond by raising drug prices in Europe and other markets to maintain elevated U.S. prices. Wealthy European nations, which often receive new medicines soon after the U.S., are likely to be affected first. In lower-income countries, companies may delay or avoid launching new drugs altogether, limiting access to life-saving treatments.

The Trump administration argues that higher global drug prices would fund pharmaceutical innovation, which it claims is disproportionately financed by U.S. consumers. However, the plan’s reliance on voluntary action and lack of implementation details have drawn criticism from industry experts.


Why It Matters?

Trump’s drug-pricing plan could disrupt global pharmaceutical markets, with significant implications for access to medicines and healthcare costs. Wealthy nations may face higher prices, while lower-income countries risk losing access to new treatments altogether.

The plan also highlights the complexities of implementing reference pricing in the U.S., where drugmakers are unlikely to voluntarily disclose negotiated discounts. If poorly executed, the policy could exacerbate global health inequities and strain international relations.

For the pharmaceutical industry, the plan poses a challenge to balancing profitability with equitable access. Companies like Roche have already warned that the policy could jeopardize U.S. investments in research and development.


What’s Next?

The Trump administration will need to address the logistical challenges of implementing reference pricing, including securing voluntary price disclosures from drugmakers. Meanwhile, European nations may need to reassess their pricing strategies to mitigate the impact of higher drug costs.

Global health organizations and policymakers will likely push for solutions that balance affordability with innovation, such as value-based pricing models. Investors and industry stakeholders should monitor the policy’s rollout and its potential impact on pharmaceutical markets and healthcare access worldwide.

Source
Tags: Trump
Previous Post

Walmart’s Tariff-Driven Price Hikes Signal Broader Inflationary Pressures Across Industries

Next Post

Musk’s xAI Blames Unauthorized Tampering for Controversial ‘White Genocide’ Responses

Recommended For You

Trump to Raise Steel and Aluminum Tariffs to 50% Amid US Steel-Nippon Deal Announcement

by Team Lumida
16 hours ago
Trump Announces 25% Tariffs on Mexico and Canada, Targeting Border Security and Trade

Key Takeaways: Powered by lumidawealth.com President Trump announced an increase in steel and aluminum tariffs from 25% to 50%, citing the need to protect American workers and industries. The...

Read more

US-China Trade Talks ‘Stalled,’ Trump-Xi Call May Be Needed, Says Treasury Secretary Bessent

by Team Lumida
2 days ago
US-China Trade Talks ‘Stalled,’ Trump-Xi Call May Be Needed, Says Treasury Secretary Bessent

Key Takeaways: Powered by lumidawealth.com US Treasury Secretary Scott Bessent described US-China trade talks as “a bit stalled” and suggested a call between President Trump and President Xi Jinping...

Read more

Trump’s Team Prepares Alternative Tariff Strategy Amid Legal Challenges

by Team Lumida
2 days ago
Fed Official Warns of Inflation Risks Under Trump Presidency

Key Takeaways: Powered by lumidawealth.com A federal trade court ruled Trump’s use of emergency economic powers to impose sweeping tariffs as illegal, but an appeals court has temporarily allowed...

Read more

Trump Pressures Fed Chair Powell to Cut Interest Rates, Citing Economic Disadvantage

by Team Lumida
2 days ago
Will September’s Fed Rate Cuts Surprise Investors? Here’s What Deutsche Bank Predicts

Key Takeaways: Powered by lumidawealth.com President Trump met with Federal Reserve Chair Jerome Powell, urging him to lower interest rates, claiming current levels put the U.S. at an economic...

Read more

Federal Trade Court Strikes Down Trump’s Global Tariffs, Citing Lack of Authority

by Team Lumida
3 days ago
Federal Trade Court Strikes Down Trump’s Global Tariffs, Citing Lack of Authority

Key Takeaways: Powered by lumidawealth.com The U.S. Court of International Trade ruled that President Trump lacked the authority to impose sweeping global tariffs under the International Emergency Economic Powers...

Read more

Germany’s Unemployment Rises in May Amid Economic Uncertainty and Corporate Job Cuts

by Team Lumida
4 days ago
Germany’s Unemployment Rises in May Amid Economic Uncertainty and Corporate Job Cuts

Key Takeaways: Powered by lumidawealth.com Seasonally adjusted jobless claims in Germany increased by 34,000 in May, significantly exceeding economists’ expectations of a 14,000 rise. The unemployment rate remained steady...

Read more

EU and U.S. Agree to Fast-Track Trade Talks After Trump Delays Tariffs

by Team Lumida
5 days ago
EU and U.S. Agree to Fast-Track Trade Talks After Trump Delays Tariffs

Key Takeaways: Powered by lumidawealth.com The European Union and the U.S. have agreed to accelerate trade negotiations following a phone call between European Commission President Ursula von der Leyen...

Read more

Macron Courts Southeast Asia Amid U.S.-China Trade Tensions, Promises €9 Billion in Deals

by Team Lumida
5 days ago
Macron Courts Southeast Asia Amid U.S.-China Trade Tensions, Promises €9 Billion in Deals

Key Takeaways: Powered by lumidawealth.com French President Emmanuel Macron is leading efforts to strengthen ties with Southeast Asia, offering €9 billion in deals and defense cooperation during his visit...

Read more

China’s Industrial Profits Rise 3% in April Despite U.S. Tariffs, Boosted by Government Subsidies

by Team Lumida
5 days ago
China’s Financial Overhaul: Xi’s Strategy to Rebalance $9.1 Trillion Debt Crisis

Key Takeaways: Powered by lumidawealth.com China’s industrial profits grew 3% year-on-year in April, up from 2.6% in March, driven by a government trade-in program and strong demand for high-tech...

Read more

Swiss Exports to U.S. Plunge 36% in April Amid Trump’s Tariff Policy

by Team Lumida
5 days ago
Swiss Exports to U.S. Plunge 36% in April Amid Trump’s Tariff Policy

Key Takeaways: Powered by lumidawealth.com Swiss exports to the U.S. fell 36% in April compared to March, while imports from the U.S. dropped 15%, reflecting the impact of President...

Read more
Next Post
Musk and Trump’s Friendship: What It Means for the EV Market

Musk’s xAI Blames Unauthorized Tampering for Controversial ‘White Genocide’ Responses

Fed Official Warns of Inflation Risks Under Trump Presidency

Trump’s 30% China Tariffs Likely to Stay Until Late 2025, Analysts Predict

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Why Alibaba’s $2.8 Billion AI Investment Could Shake Up the Market

Manus AI Partners with Alibaba’s Qwen Team to Disrupt AI Industry

March 12, 2025
Walmart Expands Logistics Services Beyond Its Marketplace: What This Means for Investors

Walmart Expands Logistics Services Beyond Its Marketplace: What This Means for Investors

August 27, 2024
China’s Financial Overhaul: Xi’s Strategy to Rebalance $9.1 Trillion Debt Crisis

China’s Imports of U.S. Commodities and Cars Plunge Amid Escalating Trade War

March 21, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018